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I. Executive Summary 
 
The Joint Standing Committee on Insurance and Financial Services (Committee) of the 126th 
Maine Legislature directed the Bureau of Insurance (Bureau) to review LD 1600, An Act to 
Require Health Insurers to Provide Coverage for Human Leukocyte Antigen Testing to Establish 
Bone marrow Donor Transplantation Suitability.  The review was conducted as required by Title 
24-A, Section 2752.  This document and review is a collaborative effort of NovaRest, Inc., an 
actuarial consulting firm, and the Bureau. 
 
LD 1600 requires that all health insurance policies provide coverage for laboratory fees arising 
from human leukocyte antigen (HLA) testing performed to establish bone marrow 
transplantation suitability, up to $150.   
 
The bill provides “(2)  Prohibition.  A testing facility may not bill, charge, collect a deposit from, 
seek payment or reimbursement from or seek recourse against an individual covered under the 
policy or contract or a person acting on behalf of the individual for any portion of the laboratory 
fees.”  We are uncertain regarding the intent of this provision.  First, because insurance carriers 
are only required to cover laboratory fees up to $150 the bill appears to prohibit testing facilities 
from charging more than $150.   We note the Bureau of Insurance does not typically regulate 
testing facilities and the $150 limitation would be especially difficult to enforce against out-of-
state testing facilities.   Second, if the intent is to require insurance coverage of the testing with 
no cost-sharing, we would suggest language requiring the insurance contract to cover without 
applying the deductible, coinsurance or copays.  
 
For patients diagnosed with leukemia, lymphoma and other life-threatening diseases, a bone 
marrow or cord blood transplant may be their best or only hope for a cure. However, 
approximately 70% of patients who need a transplant do not have a matching donor in their 
family.1  Outcomes of unrelated donor transplants are approaching the rates of related donor 
transplants. In 2010, overall survival rates at one year were 71 percent (unrelated donor) and 78 
percent (related donor).2  Because the Bone Marrow Donor Worldwide Registry (BMDW) now 
comprises over six million HLA-typed volunteer donors, the chance of identifying an HLA 
serologically identical donor has increased dramatically.3 
 
                                                 
1 Be the Match, How We Help Patients, Accessed 1/18/14, http://bethematch.org/About-Us/How-we-help-patients/ 
2 U.S. Department of Health and Human Services, Understanding bone marrow and cord blood transplants, Accessed 1/28/14, 
http://bloodcell.transplant.hrsa.gov/transplant/understanding_tx/transplant_faqs/index.html#Survival_unrelated_related 
3 Bone Marrow Transplantation, Unrelated Donor Identification, Accessed 1/18/14, 
http://www.nature.com/bmt/journal/v26/n4/full/1702529a.html 
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Bone marrow screening tests are not included in the State’s essential benefits package or the 
essential health benefits (EHBs) set by the Affordable Care Act, but transplant coverage is.  
Currently, most insurance carriers do provide coverage for potential donor screening testing 
done for a particular recipient.  The proposed mandate would extend coverage to testing 
without a potential transplant recipient. 
 
The National Organ Transplant Act (NOTA) in 1984, led to the creation of the National Bone 
Marrow Donor Registry (NBMDR) in 1987. Funding for the Registry comes from both military 
(Navy) and civilian (National Institutes of Health) branches of the federal government.   
 
Potential donors without insurance coverage for the screening test may get tested for free at a 
NMDP bone marrow drive or through a free mail-in kit.  The free tests are supported by 
donations or funding from NMDP. As of July 2009, the national Bone Marrow Transplant Registry 
in the US began to offer free registration testing to those potential unrelated donors that sign up 
for the transplant registry.   
 
The “Be The Match” website states the target recruiting ages for new registry members is 18 to 
44. “This is based on medical research that shows younger donors are best for patients and 
provide the greatest chance for transplant success,” the website explains. “Because of this, 
doctors request donors in the 18 to 44 age group over 90% of the time.”  Individuals ages 45 to 
60 who want to join the bone marrow registry must do so online and will be asked to make a 
$100 payment to cover expenses.  Currently much of the testing is funded through nonprofit 
organizations or fund raising, but that funding is not guaranteed in the future. 
 
NovaRest, an actuarial consulting firm hired by the Bureau, estimated the premium increase to 
be $0.01 per member per month (PMPM) if there is cost sharing and $0.02 PMPM if no cost 
sharing is allowed based on $125 average cost for the testing. The Affordable Care Act (ACA) 
requires States to defray the cost of mandated benefits not included in the Essential Health 
Benefits (EHB).  The estimated increased coverage due to this mandate would be approximately 
$48,000 per year.  
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II. Background 
 
The Joint Standing Committee on Insurance and Financial Services (Committee) of the 126th 
Maine Legislature directed the Bureau of Insurance (Bureau) to review LD 1600, An Act to 
Require Health Insurers to Provide Coverage for Human Leukocyte Antigen Testing to Establish 
Bone Marrow Donor Transplantation Suitability.  The review was conducted as required by Title 
24-A, Section 2752.  This document and review is a collaborative effort of NovaRest, Inc., an 
actuarial consulting firm, and the Bureau.  In addition to the statutory criteria, the Committee 
asked that the review provide an analysis of: 
 
• The extent to which coverage of bone marrow screening tests are included in the State’s 
essential benefits package and covered by existing health plans, including whether 
carriers put a limit on the number of potential donors who are provided coverage for 
screening tests; 
• Whether existing health care plans provide coverage for laboratory fees associated with 
donor drives or other widespread testing of unrelated donors; 
• Whether copayments, deductibles or other cost-sharing requirements are imposed on 
existing coverage and, if this bill were enacted, an analysis of the financial impact of an 
allowance for cost-sharing compared to coverage without cost-sharing; 
• Whether there are any comparative research studies documenting the potential savings 
in health care costs through facilitating bone marrow transplantation versus other 
treatments; 
• If the bill expands coverage beyond the essential benefits package, the estimated costs to 
the State to defray the costs of including the coverage in qualified health plans; and 
• Information on the estimated and actual costs of providing this coverage in the other 
New England states that have enacted similar laws, including information on whether 
initial costs of coverage may have moderated since enactment. 
 
LD 1600 requires that all individual, group health and health maintenance organization (HMO) 
insurance policies provide coverage for laboratory fees up to $150 arising from human leukocyte 
antigen testing performed to establish bone marrow transplantation suitability in accordance 
with the following requirements:  
 
A. The individual covered under the policy or contract must meet the criteria for testing 
established by the National Marrow Donor Program, or its successor organization;  
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B. The testing must be performed in a facility that is accredited by a national accrediting 
body with requirements that are substantially equivalent to or more stringent than those of 
the College of American Pathologists and is certified under the federal Clinical Laboratories 
Improvement Act of 1967, 42 United States Code, Section 263a; and 
 
C. At the time of the testing, the individual covered under the policy or contract must 
complete and sign an informed consent form that authorizes the results of the test to be 
used for participation in the National Marrow Donor Program, or its successor organization, 
and acknowledges a willingness to be a bone marrow donor if a suitable match is found. 
 
The bill provides “(2)  Prohibition.  A testing facility may not bill, charge, collect a deposit from, 
seek payment or reimbursement from or seek recourse against an individual covered under the 
policy or contract or a person acting on behalf of the individual for any portion of the laboratory 
fees.”  We are uncertain regarding the intent of this provision.  First, because insurance carriers 
are only required to cover laboratory fees up to $150 the bill appears to prohibit testing facilities 
from charging more than $150.   We note the Bureau of Insurance does not typically regulate 
testing facilities and the $150 limitation would be especially difficult to enforce against out-of-
state testing facilities.   Second, if the intent is to require insurance coverage of the testing with 
no cost-sharing, we would suggest language requiring the insurance contract to cover without 
applying the deductible, coinsurance or copays.  
 
Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are 
procedures that restore stem cells that have been destroyed by high doses of chemotherapy 
and/or radiation therapy, due to disease. There are three types of transplants: 
o In autologous transplants, patients receive their own stem cells. 
o In syngeneic transplants, patients receive stem cells from their identical twin. 
o In allogeneic transplants, patients receive stem cells from their brother, sister, or parent. 
A person who is not related to the patient (an unrelated donor) also may be used.4 
 
The requirements of LD 1600 will potentially increase the number of matched patients to 
suitable donors.  Every four minutes someone is diagnosed with a blood cancer, like leukemia. 
For many, their only hope for a cure is a bone marrow transplant.5  Matching a patient with a 
                                                 
4 National Cancer Institute, Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation, Accessed 1/29/14, 
http://www.cancer.gov/cancertopics/factsheet/Therapy/bone-marrow-transplant 
5 Be the Match, Transplant Basics, Accessed 1/28/14, http://bethematch.org/Transplant-Basics/ 
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donor is much more complex6 than finding two people with the same blood type.  The donor’s 
stem cells must have similar genetic markers as the patient’s. These markers are called human 
leukocyte antigens or HLA type.7 
 
The common procedure in searching for a bone marrow donor for a particular patient is first to 
examine the patient’s parents, brothers, and sisters in search of an HLA-identical donor.  If no 
identical individuals are found, then the search is begun for an unrelated donor.8 
 
Doctors look for a donor with a close HLA match to the patient. This close HLA match is the most 
important factor in finding the best donor for a patient.9 
  
The National Organ Transplant Act (NOTA) in 1984, led to the creation of the National Bone 
Marrow Donor Registry in 1987. Start-up funding for the Registry came from both military 
(Navy) and civilian (National Institutes of Health) branches of the federal government.   
 
The National Marrow Donor Program (NMDP) requires evaluation of donor-recipient 
histocompatibility matching prior to unrelated hematopoietic cell transplantation (HCT). The 
minimum acceptable match was originally defined by serologic splits (antigen level of resolution) 
at these 3 loci (6 possible antigens) and required at least 5 matches, that is, a 5 of 6 match. This 
requirement has changed little over the years. Currently, to request a donor for transplantation, 
the minimal acceptable level of matching remains a 5 of 6 match for a HLA donor. 
 
In 1990, the NMDP became a separate private nonprofit organization in Minneapolis, and was 
contracted by Health and Human Services (HHS) to operate the registry, replacing the Red Cross. 
Responsibility for maintaining the public US BMT donor registry resides with the Division of 
Transplantation of the Healthcare Systems Bureau of the Health Resources & Services 
Administration (HRSA) of HHS. HRSA does not operate the registry itself, but contracts out the 
federally-funded service. For the renewal to occur each time, Congress must pass enabling 
legislation that is then signed into law by the President. To date, at each renewal, the registry 
contract has been awarded to the NMDP. The Office of Naval Research continues to fund 
scientific research and minority donor testing, conducted by the NMDP. 
                                                 
6 Be the Match, Matching patients with donors, Accessed 1/28/14, http://bethematch.org/Transplant-Basics/Matching-patients-
with-donors/ 
7 Blood & Marrow Transplant Information Network, Finding a Donor, Accessed 1/28/14, 
http://www.bmtinfonet.org/before/findingdonor 
8 American Society of Hematology, Blood, Accessed 1/28/14, 
http://bloodjournal.hematologylibrary.org/content/87/2/800.full.pdf 
9 Be the Match, Matching patients with donors, Accessed 1/28/14, http://bethematch.org/Transplant-Basics/Matching-patients-
with-donors/ 
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Legislation in 1991 led to the first allocation of federal funds for donor typing. Continued citizen 
efforts to include the recruitment of donors from under-represented racial/ethnic groups as a 
program priority, led to new NMDP recruitment programs starting in the mid-90s, when existing 
ethnic-specific recruitment groups were incorporated into the NMDP Network for the first 
time.10  
 
Some money for the Bone Marrow Screening Fund has come from the voluntary contribution 
check off on tax forms in Maine.  This was recently eliminated.  Other local funding comes from 
the recipient, through family and friends raising money for donor drives.  Michael’s Fund and the 
Maine Leukemia Foundation help fund donors as well. 
 
More than 17,900 bone marrow transplants were performed in the United States in 2011a. 
 
Number of 
Transplants 
Performeda 
Type of Transplant 
  
10,403b Autologous (the cells for transplant were provided by the patient) 
3,114 
Related allogeneic 
(the cells for transplant were provided by the patient's sibling 
or another family member) 
4,421 Unrelated allogeneic (the cells for transplant were provided by a volunteer donor) 
 
a. These data are of transplants performed from January 1, 2008 through December 31, 2011. These data were reported to the 
Center for International Blood and Marrow Transplant Research® (CIBMTR).  
b. Many U.S. transplant centers voluntarily report autologous transplant data to the CIBMTR. Because these data are not required to 
be reported, this number represents only a portion of the actual autologous transplants performed.11 
 
The extent to which coverage of bone marrow screening tests are included in the State’s 
essential benefits package and covered by existing health plans, including whether carriers put 
a limit on the number of potential donors who are provided coverage for screening tests; 
 
Currently, bone marrow screening tests are not included in the State’s essential benefits 
package or the essential health benefits (EHBs) set by the Affordable Care Act, but transplant 
                                                 
10 http://bmtbasics.org/basics-2/finding-a-donor/donor-registries-background/ 
11 Health Resources and Services Administration, General Frequently Asked Questions, Accessed 1/29/14, 
http://bloodcell.transplant.hrsa.gov/ABOUT/General_FAQs/index.html 
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coverage is.  Historically, when an insured is covered for a transplant, donor testing is covered at 
least for the patient’s immediate family. 
 
Anthem and Maine Community Health Options (MCHO) cover donor testing of unrelated donors 
under an insured member’s policy if their insured needs a transplant that has been determined 
to be medically necessary and there is no suitable familial match. They do not provide testing of 
unrelated donors under the potential donor’s policy. There is no limit to the number of 
individuals covered for testing. 
 
MEGA stated that their health benefit plans do not provide benefits to address the coverage for 
the cost of testing for bone marrow donation suitability. 
 
Aetna responded that they only cover immediate family members. 
 
Whether existing health care plans provide coverage for laboratory fees associated with donor 
drives or other widespread testing of unrelated donors; 
 
If a covered individual requires a transplant, typically the individual’s insurer will cover the 
testing of family members and other volunteer donors for the insured individual. 
 
Aetna, Cigna, Maine Community Health Options and MEGA do not provide coverage for donor 
drives or other widespread testing of unrelated donors. 
 
Harvard Pilgrim’s policy is that bone marrow donation is included in organ donor protocols.  The 
plan will cover evaluation of donor organ for tissue (histologic) HLA testing, compatibility and 
has no limits on how many tests.   They will also cover donor drives if they are billed. 
 
Cigna covers individuals being tested as donors for one of its members.  The recipient’s level of 
coverage would be specific to their plan and transplant benefits. 
 
Anthem responded that their medical policy does not specifically address donor drives but 
testing at such a drive would likely be covered, if authorized as medically necessary, and if the 
tests were submitted by a participating provider. 
 
Whether copayments, deductibles or other cost-sharing requirements are imposed on existing 
coverage and, if this bill were enacted, an analysis of the financial impact of an allowance for 
cost-sharing compared to coverage without cost-sharing 
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Depending on deductible levels and copays the cost sharing can range from 0% to 100%.  The 
financial impact would increase if there was no cost sharing, but since the total cost is estimated 
to be minimal, the added cost would be minimal.   We estimate a financial impact of $0.01 per-
member-per-month (PMPM) with cost sharing and $0.02 PMPM if no cost sharing is allowed. 
 
Aetna responded that based on Maine’s historical experience and the historical experience of 
other Northeast states with HLA mandates, they believe that implementing this proposed level 
of coverage, with and without cost-sharing, would generate an immaterial increase in premiums, 
administrative expenses and indirect costs. 
 
Cigna responded that the financial impact really does depend on the plan design and level of 
cost share, but in general the expectation is that the impact would be minimal across all types of 
costs referenced. 
 
Anthem responded that they estimate a claims cost of $0.034 PMPM, which would drive a 
minimal impact on premiums. They do not anticipate an impact on administrative expenses.  
 
Whether there are any comparative research studies documenting the potential savings in 
health care costs through facilitating bone marrow transplantation versus other treatments 
 
There are medical studies quantifying effectiveness for various aspects of types of treatments.  
An article provided by the National Marrow Donor Program (NMDP) concluded that “the time 
taken from diagnosis to transplant is recognized to adversely affect patient outcome, and 
provision of unrelated donors has been identified as a key source of delay.”12  The article 
identified areas in need of improvement to shorten the time a donor would be available such as 
recruiting from ethnic minority groups, donor registries may need to increase the number of 
new donors typed to high resolution for better matches and moving towards better donor 
quality instead of just high numbers of donors. 
 
Also an article in the publication Stem Cells13 analyzed five studies on the cost-effectiveness and 
third-party charges of bone marrow transplants.   The conclusion was that related matches are 
the most cost-effective procedure for many diseases, however, they felt that future treatment 
advances would increase the cost-effectiveness of unrelated transplants.  
                                                 
12 Bone Marrow Transplantation (2013) 48, 210-219 
13 Westerman, I. L. and Bennett, C. L. (1996), A Review of the Costs, Cost-Effectiveness and Third-Party Charges of Bone Marrow 
Transplantation. Stem Cells, 14: 312–319. doi: 10.1002/stem.140312 
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If the bill expands coverage beyond the essential benefits package, the estimated costs to the 
State to defray the costs of including the coverage in qualified health plans 
 
We estimate the cost to the state beyond the essential benefits package would be less than 
$48,000 a year. 
 
Information on the estimated and actual costs of providing this coverage in the other New 
England states that have enacted similar laws, including information on whether initial costs 
of coverage may have moderated since enactment. 
 
In Anthem’s initial response they indicated “of the four states identified, there are Anthem Plans 
in New Hampshire and Connecticut.  Looking at Maine, New Hampshire, and Connecticut 
Anthem’s analysis indicates a cost of $0.034 per member per month.” 
 
Connecticut’s cost impact did not vary significantly over the past three years.  The total 
projected cost remained at $0.05 PMPM for that period.  While Connecticut does not cap the 
reimbursement it does not allow the cost share to exceed 20% of the cost of the test. Anthem 
provided the following table of number and cost of claims for Connecticut and New Hampshire. 
 
Connecticut:  
Year 2011 2012 2013 Average 
Claim Count 637 930 693 753 
Paid Claims $27,748 $36,687 $27,434 $30,623 
 
New Hampshire:  
Year 2011 2012 2013 Average 
Claim Count 287 362 265 305 
Paid Claims $21,644 $18,153 $13,528 $17,775 
 
Anthem noted significantly higher expenses for screening tests in New Hampshire of about $0.26 
PMPM in 2010. At that time New Hampshire did not have a cap in place and there were abuses 
by the facility and registry documented by the New Hampshire Attorney General in February 
2012.  Insurance companies were billed between $700 and $4,300 for tests that cost a fraction 
of those amounts.14 
 
Cigna responded by saying “since it is already standardly covered by Cigna, our pricing team says 
the mandate would not have a notable impact on costs.  Other than the issue in New Hampshire 
                                                 
14 Press Release, New Hampshire, Department of Justice, Office of the Attorney General, February 2, 2012 
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where the donor organization was investigated by the attorney general, similar mandates in 
other states have not been a big issue to Cigna.” 
 
Final review by CIGNA of the 2013 claim data in New Hampshire continues to show utilization is 
low for insured business. As they had only 21 claims for HLA screening in 2013, it would be 
difficult to determine if it costs have moderated since enactment or to predict if there will be 
increases. It seems to reason that very aggressive recruiting in bone marrow donor drives would 
likely increase utilization but that would not be predictable. The range of the 21 charges 
submitted to Cigna for the 2013 claims was $49-$337.  These billed charges totaled $4,431.66 
and Cigna paid $1,741.66 for HLA screening in 2013. Typically Cigna paid less than the billed 
charges due to contracted rates and in all cases but one, Cigna paid less than $150. The range of 
paid claims was $16.56 to $149.40, with one charge paid at $161.66.  Member cost share 
(coinsurance, copay, deductible) was $0 with the exception of one member who paid $27.59 
toward a deductible. 
 
Harvard Pilgrim noted they “cannot provide costs and volumes before and after the mandate.  
Anecdotally we have not seen utilization spike dramatically, but we were providing coverage for 
the test prior to the mandate in New Hampshire so it isn’t clear how the mandate impacted 
behavior.” 
 
Compass Health Analytics, an actuarial consulting firm, prepared a review of state-mandated 
health insurance benefits for the Commonwealth of Massachusetts in January 2013.  In their 
report they estimated the premium impact of the HLA mandate to be $0.0055 or 0%. 
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III. Social Impact 
 
A. Social Impact of Mandating the Benefit 
 
1. The extent to which the treatment or service is utilized by a significant portion of the 
population. 
 
Nationally, each year, nearly 20,000 people age 0-74 years might benefit from a potential life–
saving bone marrow transplant.15   
 
The NMDP Network has more than four million volunteer donors and has Donor Centers and 
Transplant Centers in 14 countries. About 40% of the transplants facilitated by the NMDP 
involve either a U.S. patient receiving bone marrow and/or stem cells from an international 
donor, or an international patient receiving bone marrow/stem cells from a U.S. donor. The 
NMDP coordinates more than 130 stem cell transplants each month.16 
 
This year, more than 130,000 Americans will be diagnosed with a serious blood disease.  
Leukemia (a blood cancer) will strike 44,000 Americans this year, including 3,500 children.  It will 
kill about half of the adults and about 700 of the children.17 
 
Testimony indicated that in Maine between 1,000 to 2,000 people are tested for donor 
compatibility each year, at a cost of $100 to $150 per test.  In 2012 1,600 donors joined the 
registry in Maine.  According to the Bone Marrow Donor Program, since its inception 226 
Mainers have become donors and 263 have received transplants.  Most of those have taken 
place in the past ten years. 
 
2.   The extent to which the service or treatment is available to the population. 
 
HLA testing is available at donor centers, online and through donor drives. 
 
There are currently no NMDP Donor Centers in Maine, however, the following Donor Centers 
cover all or part of Maine.  
                                                 
15 Health Resources and Services Administration, How many people need a bone marrow transplant?, Accessed 1/29/14, 
http://bloodcell.transplant.hrsa.gov/about/general_faqs/index.html  
16 Surgey.com, Bone Marrow Transplantation, Accessed 1/29/14, http://www.surgery.com/procedure/bone-marrow-
transplantation/demographics 
17 Institute for Justice, Bone Marrow Statistics, Accessed 1/29/14, http://ij.org/bone-marrow-statistics 
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Dana-Farber Cancer Institute  
450 Brookline Avenue 
Boston, MA 02215 
(617) 632-2561 
(866) 875-3324 
http://www.dfci.org/nmdp 
The HLA Registry  
A Division of Community Blood Services 
102 Chestnut Ridge Road 
Montvale, NJ 07401 
(201) 389-0480 
(800) 336-3363 
http://www.communitybloodservices.org 
National Marrow Donor Program Northeast District 
700 Spring Garden Street 
Philadelphia, PA 19123-3594 
(877) 868-8010 
(877) 868-8010 
http://www.BeTheMatch.org 
 
 
3.    The extent to which insurance coverage for this treatment is already available. 
 
Aetna considers compatibility testing of prospective donors who are members of the immediate 
family (first-degree relatives, i.e. parents, siblings and children) and harvesting and short-term 
storage of peripheral stem cells or bone marrow from the identified donor medically necessary 
when an allogeneic bone marrow or peripheral stem cell transplant is authorized by Aetna.  
Aetna does cover testing of immediate family members.   
 
Harvard Pilgrim’s policy is that bone marrow donation is included in organ donor protocols.  The 
plan will cover evaluation of donor organ for tissue (histologic) HLA testing, compatibility and 
has no limits on how many tests. They also will cover the cost for donor drives, if billed. 
 
Cigna covers screening if the recipient is in transplant case management and is part of the 
Lifesource contracts. 
 
Anthem covers testing of unrelated donors if there is not a suitable familial match and the 
insured needs a transplant that has been determined to be medically necessary.  
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4.     If coverage is not generally available, the extent to which the lack of coverage results in 
a person being unable to obtain the necessary health care treatment. 
 
Lack of a substantial number of potential donors available on the National Registry could lead to 
delays in treatment for the recipient of the transplant.  Without insurance coverage the $100 
cost for the screening test could deter potential donors. 
 
The Dana-Farber website states: “If your insurance will not cover the tissue-typing fee, we are 
able to cover the cost of your test. However, if you would like to make a tax-deductible donation 
to help our recruitment efforts, we would greatly appreciate it.” 
 
Without health insurance covering the cost of testing, either the donor’s funds or donations are 
used to pay for the swab testing.  According to written testimony by Steven and Lisa Cota when 
Steve’s lifelong friend Gregory, “Gregg” Sanborn needed a transplant they had to turn to 
donations to defray the costs.  “As a result of this effort to find a donor and promote the need 
for donors, over a thousand people were added to donor roles.”  
 
In his testimony Patrick Roy stated “everyone should want the chance to save a life, and they 
should have that opportunity.  At the time of my swab test, if I had had to cover the $100 swab 
test, unfortunately I would not have done so.” 
 
According to testimony by Todd Ellison “having bone marrow testing covered by insurers (thus 
alleviating the burden of cost to those tested) will allow a greater number of people to be tested 
and added to the roles of potential bone marrow donors.  Increasing the number of possible 
donors will ultimately result in increasing the number of “matches” for bone marrow 
transplantation. 
 
5.    If coverage is not generally available, the extent to which the lack of coverage involves 
unreasonable financial hardship.  
  
The lack of insurance coverage for the initial test may be a deterrent for individuals that might 
otherwise be willing to be tested.  Patients who are diagnosed with cancer and need a bone 
marrow transplant may be faced with covering the cost associated with the initial testing 
themselves, multiplied times many individuals and tests.  In most cases the insurance of an 
insured patient will cover the testing of at least family members and potentially unrelated 
potential donors.  If the insurance does not cover needed testing, the potential cost for a patient 
paying could be high. 
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Many cheek swab tests range in price from $100 to $150.  A prospective donor can also order a 
cheek swap kit from various non-profit organizations.  There are organizations such as Swab a 
Cheek and Cheekswab that are dedicated to increase the number of donors.  However, if these 
organizations do not receive adequate funding they may not be able to continue. 
 
As John P. Gallivan testified, “It is a shame that families like mine are forced to spend an 
exorbitant amount of money just to find a match.  We didn’t want people to be hesitant to get 
tested in Wethersfield, so with the help of our friends we covered the cost of the drive 
ourselves.” 
 
6.    The level of public demand and the level of demand from providers for this treatment or 
service.  
 
During the public hearing for LD 1600, advocates for this bill testified about the battle to find 
suitable donors and the need to defray the cost for those willing to enter the registry.  There are 
advocacy groups dedicated to increasing public awareness about registering to become a bone 
marrow donor.        
 
Demand for this benefit comes “primarily from prospective recipients and their families and 
from the National Marrow Donor Program. The NMDP indicated they receive approximately 
1,200 new requests for registry searches per month nationally. One study in 2001 indicated that 
approximately 15 percent of patient searches do not find a match.”18 
 
7.    The level of public demand and the level of demand from the providers for individual or 
group coverage of this treatment. 
 
In testimony from Patricia Lang, the director of the Rhode Island Blood Center she stated that 
with the insurance mandates in the New England states their file of registered potential donors 
has grown from 35,000 to 95,000 
 
8.   The likelihood of meeting a consumer need as evidenced by the experience in other 
states. 
 
Evidence in other states is limited.  Rhode Island, Massachusetts, Missouri and New Hampshire 
                                                 
18 Review and Evaluation of Public Act 09-188, An Act Concerning Wellness Programs and Expansion of Health Insurance 
Coverage, University of Connecticut, December 2009. 
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have already passed similar legislation.  Even with the support of the insurance mandate, 
though, less than 50% of those taking the screening test have insurance coverage.  
 
9.    The relevant findings of the state health planning agency or the appropriate health 
system agency relating to the social impact of the mandated benefit. 
 
State agencies did not provide findings pertaining to the proposed legislation. 
 
10.    The alternatives to meeting the identified need. 
 
Close relatives, especially brothers and sisters, are more likely than unrelated people to be HLA-
matched. However, only 25 to 35 percent of patients have an HLA-matched sibling.19 
 
The alternative for the health insurance company paying for coverage is that most patients will 
reach out to friends, family, non-profit organizations and even employers to help defray the cost 
of testing when willing participants cannot afford the $100-$150.  Per the testimony of Steven 
Cote “family, friends and communities banded together to host stem cell donor drives: monies 
were donated to pay for those who wanted desperately to help in some way but could not 
afford the $100 fee for the non-invasive swab test.” 
 
11.   Whether the benefit is a medical or a broader social need and whether it is inconsistent 
with the role of insurance and the concept of managed care.   
 
HLA testing required by LD 1600 does not meet a medical need for the person being tested as a 
potential donor.  The coverage is not inconsistent with the role of insurance to provide medically 
necessary services for a condition.  However this mandate may step outside of the role of 
insurance in that it requires providers to pay for testing to establish bone marrow donor 
transplantation suitability unrelated to the need of an insured member. It is unusual for health 
insurance companies to reimburse for a test that will not necessarily benefit their insured.  For 
example, Aetna already covers the cost of family member testing.  The testing is provided for a 
person who needs a transplant, and not for potential future use. 
 
It is possible that the passing of this legislation will meet a broader social need in that it would 
encourage more individuals to get tested and be available as donors.  This outcome would have 
the potential to assist more patients in need of life-saving bone marrow transplants.  At any 
                                                 
19 National Cancer Institute, Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation,  
Accessed 1/29/14, http://www.cancer.gov/cancertopics/factsheet/Therapy/bone-marrow-transplant  
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given time, about 7,500 American are actively searching the national registry for an unrelated 
donor.  Only 2 percent of the population is on the national registry.  At least 1,000 people die 
each year because they cannot find a matching donor.20 
 
The benefit is reduced since a significant number of those on the national bone marrow registry 
cannot be located or will not donate when asked to do so.  The percentages of donors who are 
available and willing are:  65 percent for Caucasians; 47 percent for Hispanics; 44 percent for 
Asians; 34 percent for African-Americans. 
 
12.   The impact of any social stigma attached to the benefit upon the market. 
 
There is no known social stigma associated with being tested as a potential donor. 
 
13.   The impact of this benefit upon the other benefits currently offered. 
 
This legislation could impact the number of transplants performed, if it results in more donor 
matches.  
 
14.   The impact of the benefit as it relates to employers shifting to self-insurance and the 
extent to which the benefit is currently being offered by employers with self-insured 
plans. 
 
As premiums increase due to mandated benefits, some employers choose to self-insure in order 
to have more control over the benefits they provide to employees and to control the cost of 
premiums.  We cannot estimate the impact on premiums, but believe there would be no shifting 
to self-insured plans. 
 
15.  The impact of making the benefit applicable to the state employee health insurance 
program. 
 
Aetna’s analysis indicates that the impact would be immaterial. 
                                                 
20 Institute for Justice, Op cit. 
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IV. Financial Impact 
 
B.  Financial Impact of Mandating Benefits 
 
1.   The extent to which the proposed insurance coverage would increase or decrease the 
cost of the service or treatment over the next five years. 
 
If the service is covered by insurance it is logical to expect the increase in demand and 
availability of insurance coverage to increase the cost of the service.   It is also possible that the 
mandate could lead to new testing technologies that may be more expensive and increase the 
overall cost of the service. Since this act covers $150 per service, we expect that the cost will 
increase to that amount, especially if insured cost sharing is not allowed.   
 
2.  The extent to which the proposed coverage might increase the appropriate or 
inappropriate use of the treatment or service over the next five years. 
 
Since there will be less or no upfront cost it may be more likely that an individual is willing to get 
tested, but unwilling to make the potentially lifesaving donation should the need arise.  As 
reported by the Institute of Justice “a significant number of those on the national bone marrow 
registry cannot be located or will not donate when asked to do so.”21  The collection of marrow 
is not a simple matter and involves recovery and loss of work time.   
 
Even if all potential donors do not go through with the actual donation, it is reasonable to 
believe that the increase in matches will have a positive impact on the number of actual 
transplants that take place.  How many of these transplants will be for citizens of Maine rather 
than patients matched in other states, or other countries, is unknown. 
 
3.  The extent to which the mandated treatment or service might serve as an alternative for 
more expensive or less expensive treatment or service.   
 
Currently, there are no other widely used methods to the current HLA screening test to match 
potential donors with patients that need hematopoietic stem cell transplants. 
 
4.  The methods which will be instituted to manage the utilization and costs of the proposed 
mandate. 
                                                 
21 Institute for Justice, Op cit. 
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Typically an insurance company can limit covered services to those that are medically necessary 
for their members, but LD 1600 would not necessarily be for the benefit of the insured. The 
mandate for the HLA testing may result in carriers negotiating with preferred labs for the 
reimbursement for HLA tests. Anthem suggested that the legislation include a provision that 
allows a carrier to require the use of certain codes specified by the carrier for reimbursement. 
This would help to ensure the claims are properly adjudicated and avoid issues that have 
occurred in the past in other states. 
 
5.  The extent to which insurance coverage may affect the number and types of providers 
over the next five years. 
 
The mouth swab test can be self-administered at home and with the usage in Maine limited to 
1,000 to 2,000 tests a year we do not foresee any new providers to process the tests in the next 
five years.   
 
6.  The extent to which the insurance coverage of the health care service or providers may 
be reasonably expected to increase or decrease the insurance premium or administrative 
expenses of policyholders. 
 
Aetna did indicate “reimbursement for donor fairs would be administratively difficult if the 
claims are not submitted through a provider or entity that can submit claims electronically. 
 
Unum testified “as drafted, however, Unum is concerned that LD 1600 would include its 
supplemental critical illness insurance that has been exempt from the definition of health 
insurance with respect to mandated benefits and coverage laws, see Title 24-A MRSA 704(2), 
since that law was enacted in 2001.”  If this were true, the cost of this type of insurance would 
also increase. 
 
Aetna Response: “Based on Maine’s historical experience and the historical experience of other 
Northeast states with HLA coverage mandates, we believe that implementing this proposed 
level of coverage, with and without cost-sharing, would generate an immaterial increase in 
premiums, administrative expenses and indirect costs.” 
 
Cigna Response: “The financial impact really does depend on the plan design and level of cost 
share, but in general the expectation is that the impact would be minimal across all types of 
costs referenced.”  
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NovaRest, an actuarial consulting firm, estimated the premium increase to be $0.01 PMPM if 
there is cost sharing and $0.02 PMPM if no cost sharing is allowed. 
 
7.  The impact of indirect costs, which are costs other than premiums and administrative 
costs, on the question of the cost and benefits of coverage. 
 
There will not be any additional cost effect beyond benefit and administrative costs. 
 
8.  The impact on the total cost of health care, including potential benefits and savings to 
insurers and employers because the proposed mandated treatment or service prevents 
disease or illness or leads to the early detection and treatment of disease or illness that is 
less costly than treatment or service for later stages of a disease or illness. 
 
An article provided by the National Marrow Donor Program (NMDP) concluded that “the time 
taken from diagnosis to transplant is recognized to adversely affect patient outcome, and 
provision of unrelated donors has been identified as a key source of delay.”22   
 
According to testimony by Steve Cote “the number of registered donors will also multiply, 
leading to further matches and lives saved moving forward.”  There is potentially a savings if a 
patient is matched with a donor sooner and medical costs that would take place between the 
need for a transplant and the actual transplant are eliminated.   
 
In testimony by Ellen Guilford she stated, “I truly believe had he had a donor back in March or 
April, Gregg’s body and immune system would not have been so ravaged and it would have been 
easier for him to fight the infection that often accompanies receiving a donation.  It is having a 
registry full of potential donors waiting to help ‘us’ when we are in need that will ultimately save 
lives.” 
 
9.  The effects of mandating the benefit on the cost of health care, particularly the premium 
and administrative expenses and indirect costs, to employers and employees, including 
the financial impact on small employers, medium-sized employers and large employers. 
 
The cost of healthcare will increase to the extent that more tests are administered and the cost 
per test is increased.  Currently much of the testing is funded through nonprofit organizations, 
but that funding is not guaranteed in the future.  To the extent that insurance coverage replaces 
                                                 
22 Bone Marrow Transplantation (2013) 48, 210-219 
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the nonprofit efforts, it will not impact the total cost of health care. 
We estimate the impact on premium to be between $0.01 and $0.02 PMPM. 
 
10.   The effect of the proposed mandates on cost-shifting between private and public payers 
of health care coverage and on the overall cost of the health care delivery system in this 
State. 
 
To the extent that these services are currently covered by MaineCare and will be paid for by 
private insurance after the mandate is implemented, the cost may be shifted from the public 
payers to private payers.  Individuals with private insurance tend to use that coverage before 
using public programs, when they have access to both. 
 
This program may shift costs from current nonprofit efforts to private insurance. 
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V. Medical Efficacy 
 
C. The Medical Efficacy of Mandating the Benefit 
 
1.  The contribution of the benefit to the quality of patient care and the health status of the 
population, including any research demonstrating the medical efficacy of the treatment 
or service compared to the alternative of not providing the treatment or service. 
 
There are no alternatives for the current mouth swab testing.  The swab testing is effective in 
identifying potential donors, which increases the number of transplants that are possible.  The 
sooner a donor can be located the more effective the transplant may be. 
 
2.   If the legislation seeks to mandate coverage of an additional class of practitioners: 
 
This is not applicable. 
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VI. Balancing the Effects 
 
D. The Effects of Balancing the Social, Economic, and Medical Efficacy Considerations 
 
1.  The extent to which the need for coverage outweighs the cost of mandating the benefit 
for all policyholders. 
 
Bone marrow transplantations (BMT) are procedures that restore stem cells that have been 
destroyed by illness, high doses of chemotherapy and/or radiation therapy. For patients 
diagnosed with leukemia, lymphoma and other life-threatening diseases, a bone marrow 
transplant may be their best or only hope for a cure. Yet 70% of patients who need a transplant 
do not have a matching donor in their family23 and rely on finding a donor outside of their 
family.  
 
Currently there are other agencies that run donor drives and cover the cost of testing, but their 
continued funding is not guaranteed. 
 
2.  The extent to which the problem of coverage can be resolved by mandating the 
availability of coverage as an option for policyholders. 
 
It is likely that only those who would benefit from the services would purchase the coverage. 
This would result in an alternative coverage that would cost more than the additional cost of 
services because of the administrative charges that would be added to benefit costs. This cost 
would be reduced if the option was only available when the coverage was initially purchased, 
but it would then be less effective because many individuals would not anticipate needing the 
coverage and, therefore, would not purchase it. 
 
3.  The cumulative impact of mandating this benefit in combination with existing mandates 
on costs and availability of coverage. 
 
The estimated cost of current Maine mandates is detailed in Appendix C.  For most of these 
mandates, our estimate is based on the net impact on premiums as estimated at the time the 
mandate was enacted.  Four of the mandates – mental health, substance abuse, chiropractic, 
and screening mammograms – require carriers to report annually the amount of claims paid for 
these benefits and the estimates are based on that data.  The true cost for the Maine mandates 
                                                 
23 Be the Match, How We Help Patients, Accessed 1/18/14, http://bethematch.org/About-Us/How-we-help-patients/ 
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are impacted by the fact that:  
1.  Some services would be provided and reimbursed in the absence of a mandate. 
2. Certain services or providers will reduce claims in other areas. 
3. Some mandates are required by Federal law. 
LD 1600, 126th Maine State Legislature 
An Act to Require Health Insurers to Provide Coverage for Human Leukocyte Antigen  
Testing to Establish Bone Marrow Donor Transplantation Suitability 
 
 
24 
 
 
VII. Appendices 
LD 1600, 126th Maine State Legislature 
An Act to Require Health Insurers to Provide Coverage for Human Leukocyte Antigen  
Testing to Establish Bone Marrow Donor Transplantation Suitability 
 
 
25 
 
 
Appendix A: Letter from the Committee on Insurance and Financial Services with Proposed 
Legislation 
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Presented by Representative RANKIN of Hiram. 
Cosponsored by Senator LANGLEY of Hancock and 
Representatives: BEAVERS of South Berwick, BECK of Waterville, COOPER of Yarmouth, 
DAUGHTRY of Brunswick, GATTINE of Westbrook, KINNEY of Limington, KORNFIELD 
of Bangor, LONGSTAFF of Waterville, NADEAU of Winslow, PLANTE of Berwick, 
THERIAULT of Madawaska, Senators: MILLETT of Cumberland, PATRICK of Oxford. 
 
1             Be it enacted by the People of the State of Maine as follows: 
 
2                   Sec. 1.  24 MRSA §2317-B, sub-§12-I is enacted to read: 
 
3                    12-I.  Title 24-A, sections 2769, 2847-U and 4260.  Coverage for the cost of testing 
4             for bone marrow donation suitability, Title 24-A, sections 2769, 2847-U and 4260; 
 
5                   Sec. 2.  24-A MRSA §2769 is enacted to read: 
 
6              §2769.  Coverage for the cost of testing for bone marrow donation suitability 
 
7                    1.  Required coverage.  All individual health insurance policies and contracts must 
8             provide coverage for laboratory fees up to $150 arising from human leukocyte antigen 
9             testing performed to establish bone marrow transplantation suitability in accordance with 
10             the following requirements: 
 
11                   A.   The individual covered under the policy or contract must meet the criteria for 
12                   testing  established  by  the  National  Marrow  Donor  Program,  or  its  successor 
13                   organization; 
 
14                   B.   The testing must be performed in a facility that is accredited by a national 
15                   accrediting  body  with  requirements  that  are  substantially  equivalent  to  or  more 
16                   stringent than those of the College of American Pathologists and is certified under the 
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17                   federal  Clinical  Laboratories  Improvement  Act  of 1967,  42  United  States  Code, 
18                   Section 263a; and 
 
19                   C.  At the time of the testing, the individual covered under the policy or contract must 
20                   complete and sign an informed consent form that authorizes the results of the test to 
21                   be used for participation in the National Marrow Donor Program, or its successor 
22                   organization, and acknowledges a willingness to be a bone marrow donor if a suitable 
23                   match is found. 
 
24                    2.  Prohibition.  A testing facility may not bill, charge, collect a deposit from, seek 
25             payment or reimbursement from or seek recourse against an individual covered under the 
26             policy or contract or a person acting on behalf of the individual for any portion of the 
27             laboratory fees. 
 
28                   Sec. 3.  24-A MRSA §2847-U is enacted to read: 
 
29              §2847-U.  Coverage for the cost of testing for bone marrow donation suitability 
 
30                    1.     Required  coverage.     All  group  health  insurance  policies,  contracts  and 
31             certificates must provide coverage for laboratory fees up to $150 arising from human 
32             leukocyte antigen testing performed to establish bone marrow transplantation suitability 
33             in accordance with the following requirements: 
 
34                   A.   The individual covered under the policy, contract or certificate must meet the 
35                   criteria  for  testing  established  by  the  National  Marrow  Donor  Program,  or  its 
36                   successor organization; 
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1                   B.   The testing must be performed in a facility that is accredited by a national 
2                   accrediting  body  with  requirements  that  are  substantially  equivalent  to  or  more 
3                   stringent than those of the College of American Pathologists and is certified under the 
4                   federal  Clinical  Laboratories  Improvement  Act  of 1967,  42  United  States  Code, 
5                   Section 263a; and 
 
6                   C.   At the time of the testing, the individual covered under the policy, contract or 
7                   certificate must complete and sign an informed consent form that authorizes the 
8                   results of the test to be used for participation in the National Marrow Donor Program, 
9                   or its successor organization, and acknowledges a willingness to be a bone marrow 
10                   donor if a suitable match is found. 
 
11                    2.  Prohibition.  A testing facility may not bill, charge, collect a deposit from, seek 
12             payment or reimbursement from or seek recourse against an individual covered under the 
13             policy, contract or certificate or a person acting on behalf of the individual for any portion 
14             of the laboratory fees. 
 
15                   Sec. 4.  24-A MRSA §4260 is enacted to read: 
 
16              §4260.  Coverage for the cost of testing for bone marrow donation suitability 
 
17                    1.  Required coverage.  All individual and group health maintenance organization 
18             contracts must provide coverage for laboratory fees up to $150 arising from human 
19             leukocyte antigen testing performed to establish bone marrow transplantation suitability 
20             in accordance with the following requirements: 
 
21                   A.   The individual covered under the contract must meet the criteria for testing 
22                   established by the National Marrow Donor Program, or its successor organization; 
 
23                   B.   The testing must be performed in a facility that is accredited by a national 
24                   accrediting  body  with  requirements  that  are  substantially  equivalent  to  or  more 
25                   stringent than those of the College of American Pathologists and is certified under the 
26                   federal  Clinical  Laboratories  Improvement  Act  of 1967,  42  United  States  Code, 
27                   Section 263a; and 
 
28                   C.  At the time of the testing, the individual covered under the contract must complete 
29                   and sign an informed consent form that authorizes the results of the test to be used for 
30                   participation in the National Marrow Donor Program, or its successor organization, 
31                   and acknowledges a willingness to be a bone marrow donor if a suitable match is 
32                   found. 
 
33                    2.  Prohibition.  A testing facility may not bill, charge, collect a deposit from, seek 
34             payment or reimbursement from or seek recourse against an individual covered under the 
35             contract or a person acting on behalf of the individual for any portion of the laboratory 
36             fees. 
 
37                   Sec. 5.  Exemption from review.  Notwithstanding the Maine Revised Statutes, 
38             Title  24-A,  section  2752, this  Act  is  enacted  without  review  and  evaluation by the 
39             Department of Professional and Financial Regulation, Bureau of Insurance. 
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Page 3 - 126LR2402(01)-1 
1                   Sec. 6.  Application.  The requirements of this Act apply to all policies, contracts 
2             and  certificates  subject to this  Act  that  are  executed,  delivered, issued  for delivery, 
3             continued or renewed in this State on or after January 1, 2015. For purposes of this Act, 
4             all contracts are deemed to be renewed no later than the next yearly anniversary of the 
5             contract date. 
 
6                                                                         SUMMARY 
 
7                   This bill requires health insurance coverage for laboratory fees up to $150 arising 
8             from   human   leukocyte   antigen   testing   performed   to   establish   bone   marrow 
9             transplantation suitability. 
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Appendix B: Cumulative Impact of Mandates 
Bureau of Insurance 
Cumulative Impact of Mandates in Maine 
Report for the Year 2012 
This report provides data for medical insurance coverage of mandates as required by 24-A M.R.S.A. 
§2752 and compiled by the Bureau of Insurance. While some data was provided through annual mandate 
reports by insurers, other figures were estimated as a part of the proposed mandates study. The following 
provides a brief description of each state mandate and the estimated claim cost as a percentage of 
premium.  Many of these mandates are now required by the federal Affordable Care Act (ACA).  In 
addition, the ACA requires benefits covered by the benchmark plan which includes all state mandates to 
be covered by all individual and small group plans effective January 1, 2014. A summary chart is provided 
at the end of this report. 
 
 Mental Health (Enacted 1983)  
Mental health parity in Maine for listed conditions became effective July 1, 1996, and was expanded effective 
October 1, 2003. The percentage of mental health claims paid has been tracked since 1984 and has historically 
been between 3% and 4% of total group health claims and was reported as 3.3% in 2012. Mental health claims 
stayed below 3.5%, despite the fact that an expansion of the list of conditions for which parity is required was 
fully implemented in 2005. Mental health coverage is included in the essential health benefits for individual and 
small group plans beginning 2014. This report includes claims as paid under the law requirements for 2012. 
Individual mental health claims were only 1.9% in 2012 as a mandated offer.  We have assumed that individual 
mental health claims will increase under ACA and will be similar to group claims in 2014. 
 
 Substance Abuse (Enacted 1983)  
The state mandate required the provision of benefits for alcoholism and drug dependency and applied only to 
groups of more than 20. Effective October 1, 2003, substance abuse was added to the list of mental health 
conditions for which parity is required. Effective on January 1, 2014 the federal Affordable Care Act requires 
substance abuse treatment benefits for individual and small group plans as part of the essential health benefits.  
 
The percentage of claims paid has been tracked since 1984. For 2012, substance abuse claims paid were 0.7% of 
the total group health claims. Despite implementation of the parity requirement, there was a long-term decrease 
in the percentage, likely due to utilization review, which sharply reduced the incidence of inpatient care. We 
estimate substance abuse claims will remain at the current levels going forward.  
 
 Chiropractic (Enacted 1986)  
This mandate generally requires coverage for the services of chiropractors to the extent that the same services 
would be covered if performed by a physician. Using annual experience reports from the carriers, the percentage 
of claims paid has been tracked since 1986 and, in 2012, was 1.0% of total health claims. The level has typically 
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been lower for individual than for group. We estimate the current levels going forward. Although it is likely that 
some of these costs would have been covered even in the absence of a mandate, we have no basis for estimating 
how much. We have included the entire amount, thereby overstating the impact of the mandate to some extent. 
 
 Screening Mammography (Enacted 1990)   
This mandate requires that benefits be provided for screening mammography. The U.S. Preventive Services Task 
force has recommended that screening mammograms begin at a later age and be done less frequently. While it is 
possible this will lead to reduced utilization, the American Cancer Society, The American College of 
Obstetricians and Gynecologists, and many oncologists have not accepted these recommendations. We, therefore, 
estimate the current level of 0.71% in all categories going forward. Coverage is required by ACA for preventive 
services. 
 
 Dentists (Enacted 1975)   
This mandate requires coverage for dentists’ services to the extent that the same services would be covered if 
performed by a physician. It does not apply to HMOs. A 1992 study done by Milliman and Robertson for the 
Mandated Benefits Advisory Commission estimated that these claims represent 0.5% of total health claims and 
that the actual impact on premiums is "slight." It is unlikely that this coverage would be excluded in the absence 
of a mandate. We include 0.1% as an estimate. 
 
 Breast Reconstruction (Enacted 1998)  
This mandate requires coverage for reconstruction of both breasts to produce a symmetrical appearance after a 
mastectomy. At the time this mandate was being considered in 1995, one carrier estimated the cost at $0.20 per 
month per individual. We do not have a more recent estimate. We include 0.02% in our estimate of the maximum 
cumulative impact of mandates. 
 
 Errors of Metabolism (Enacted 1995)  
This mandate requires coverage for metabolic formula and up to $3,000 per year for prescribed modified low-
protein food products. At the time this mandate was being considered in 1995, Blue Cross estimated the cost at 
$0.10 per month per individual. We do not have a more recent estimate. We include 0.01% in our estimate. 
 
 Diabetic Supplies (Enacted 1996)   
This mandate requires that benefits be provided for medically necessary diabetic supplies and equipment. Based 
on data collected in 2006, most carriers reported that there would be no cost increase or an insignificant cost 
increase because they already provide this coverage.  Based on our report we estimate 0.2%. 
 
 Minimum Maternity Stay (Enacted 1996)   
This mandate requires that if a policy provides maternity benefits, the maternity (length of stay) and newborn 
care benefits must be provided in accordance with “Guidelines for Prenatal Care.” Based on carrier responses 
indicating that they did not limit maternity stays below those recommended, we estimate no impact. 
LD 1600, 126th Maine State Legislature 
An Act to Require Health Insurers to Provide Coverage for Human Leukocyte Antigen  
Testing to Establish Bone Marrow Donor Transplantation Suitability 
 
 
33 
 
Pap Smear Tests (Enacted 1996)  
This mandate requires that benefits be provided for screening Pap smear tests. HMOs would typically cover these 
costs and, for non-HMO plans, the relatively small cost of this test would not in itself satisfy the deductible, so 
there would be no cost unless other services were also received. We estimate a negligible impact of 0.01%. 
Coverage is required by ACA for preventive services. 
 
 Annual GYN Exam Without Referral (Enacted 1996)   
This mandate only affects HMO plans and similar plans, and it requires the provision of benefits for annual 
gynecological exams without prior approval from a primary care physician. To the extent the Primary Care 
Physician (PCP) would, in absence of this law, have performed the exam personally rather than referring to an 
OB/GYN, the cost may be somewhat higher; therefore, we include 0.1%. 
 
 Breast Cancer Length of Stay (Enacted 1997)  
This mandate requires that benefits for breast cancer treatment be provided for a medically appropriate period of 
time as determined by the physician in consultation with the patient. Our report estimated a cost of 0.07% of 
premium. 
 
 Off-label Use Prescription Drugs (Enacted 1998)  
This mandate requires coverage of off-label prescription drugs in the treatment of cancer, HIV, and AIDS. Our 
1998 report stated a "high-end cost estimate" of about $1 per member per month (0.6% of premium) if it is 
assumed there is currently no coverage for off-label drugs.  Because the HMOs claimed to already cover off-label 
drugs, in which case there would be no additional cost; and, providers testified that claims have been denied on 
this basis, we include half this amount, or 0.3%. 
 
 Prostate Cancer (Enacted 1998)  
This mandate requires prostate cancer screenings if recommended by a physician, at least once a year for men 50 
years of age or older until a man reaches the age of 72. No increase in premiums should be expected for the 
HMOs that provide the screening benefits currently as part of their routine physical exam benefits. Our report 
estimated additional claims cost for non-HMO plans would approximate $0.10 per member per month. With the 
inclusion of administrative expenses, we would expect a total cost of approximately $0.11 per member per 
month, or approximately 0.07% of total premiums. 
 
 Nurse Practitioners and Certified Nurse Midwives (Enacted 1999)    
This law mandates coverage for nurse practitioners and certified nurse midwives and allows nurse practitioners 
to serve as primary care providers. This mandate is estimated to increase premium by 0.16%. 
 
 Coverage of Contraceptives (Enacted 1999)  
This mandate requires health plans that cover prescription drugs to cover contraceptives. Our report estimated an 
increase of premium of 0.8%. 
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 Registered Nurse First Assistants (Enacted 1999)  
This mandate requires health plans that cover surgical first assistants to cover registered nurse first assistants if 
an assisting physician would be covered. No material increase in premium is expected. 
 
 Access to Clinical Trials (Enacted 2000)  
This mandate requires that coverage be provided for an eligible enrollee to participate in approved clinical trials. 
Our report estimated a cost of 0.19% of premium. 
 
 Access to Prescription Drugs (Enacted 2000)  
 This mandate only affects plans with closed formularies. Our report concluded that enrollment in such plans is 
minimal in Maine and therefore the mandate will have no material impact on premiums. 
 
 Hospice Care (Enacted 2001) 
No cost estimate was made for this mandate because the Legislature waived the requirement for a study. Because 
carriers generally covered hospice care prior to the mandate, we assume no additional cost. 
 Access to Eye Care (Enacted 2001)   
This mandate affects plans that use participating eye care professionals. Our report estimated a cost of 0.04% of 
premium. 
 
 Dental Anesthesia (Enacted 2001)   
This mandate requires coverage for general anesthesia and associated facility charges for dental procedures in a 
hospital for certain enrollees for whom general anesthesia is medically necessary. Our report estimated a cost of 
0.05% of premium. 
 
 Prosthetics (Enacted 2003)  
This mandate requires coverage for prosthetic devices to replace an arm or leg. Our report estimated a cost of 
0.03% of premium for groups over 20, and a cost of 0.08% of premium for small employer groups and 
individuals. 
 
 LCPCs (Enacted 2003)  
This mandate requires coverage of licensed clinical professional counselors. Our report on mental health parity 
indicated no measurable cost impact for coverage of LCPCs. 
 
 Licensed Pastoral Counselors and Marriage & Family Therapists (Enacted 2005)   
This mandate requires coverage of licensed pastoral counselors and marriage & family therapists. Our report 
indicated no measurable cost impact for this coverage. 
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 Hearing Aids (Enacted 2007)  
This mandate requires coverage for $1,400 for each ear every 36 months for children age 18 and under. The 
mandate was phased-in between 2008 and 2010, and our report estimated a cost of 0.1% of premium. 
 
 Infant Formulas (Enacted 2008)   
This mandate requires coverage for amino acid-based elemental infant formulas for children two years of age and 
under, regardless of delivery method. This mandate is effective January 2009, and our report estimated a cost of 
0.1% of premium. 
 
 Colorectal Cancer Screening (Enacted 2008)  
This mandate requires coverage for colorectal cancer screening for persons fifty years of age or older, or less 
than 50 years of age and at high risk for colorectal cancer according to the most recently published colorectal 
cancer screening guidelines of a national cancer society. This mandate is effective January 2009. No carriers 
stated they denied coverage prior to this mandate; therefore, our report estimated no impact on premium. 
 
 Independent Dental Hygienist (Enacted 2009)   
This mandate requires individual dental insurance or health insurance that includes coverage for dental services 
to provide coverage for dental services performed by an independent practice dental hygienist. This mandate 
applies only to policies with dental coverage; therefore, there is no estimated impact on medical plan premiums. 
 
 Autism Spectrum Disorders (Enacted 2010)  
This mandate requires all contracts to provide coverage for the diagnosis and treatment of autism spectrum 
disorders for individuals five years of age or under. Coverage may be limited for applied behavior analysis to 
$36,000 per year. This mandate is effective January 2011, and our 2009 report estimated a cost of 0.7% of 
premium once the mandate is fully implemented if it included those under age 21. Because the current mandate 
only applies to those up to age five, the estimate was reduced to 0.3% of premium. 
 
 Children’s Early Intervention Services (Enacted 2010)   
This mandate requires all contracts to provide coverage for children’s early intervention services from birth to 36 
months for a child identified with a developmental disability or delay. Benefits may be limited to $3,200 per 
year. This mandate is effective January 2011, and our report estimated a cost of 0.05% of premium. 
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COST OF EXISTING MANDATED HEALTH INSURANCE BENEFITS 
Year 
Enacted Benefit 
Type of Contract 
Affected 
Est. Maximum 
Cost as % of 
Premium 
1975 
Must include benefits for dentists’ services to the extent that 
the same services would be covered if performed by a 
physician. 
All Contracts  
0.10% 
1983 Benefits must be included for treatment of alcoholism and drug dependency. All Contracts 0.70% 
1975 
1983 
1995 
2003 
Benefits must be included for Mental Health Services, 
including psychologists and social workers. 
Groups  
3.30% 
Individual 3.30% 
1986 
1994 
1995 
1997 
Benefits must be included for the services of chiropractors to 
the extent that the same services would be covered by a 
physician.  Benefits must be included for therapeutic, adjustive 
and manipulative services.  HMOs must allow limited self-
referred for chiropractic benefits. 
Group 1.0% 
Individual 0.50% 
1990 
1997 Benefits must be made available for screening mammography. 
Group 0.71% 
Individual 0.71% 
1995 
Must provide coverage for reconstruction of both breasts to 
produce symmetrical appearance according to patient and 
physician wishes. 
All Contracts 
0.02% 
1995 
Must provide coverage for metabolic formula and up to 
$3,000 per year for prescribed modified low-protein food 
products. 
All Contracts 
0.01% 
1996 
If policies provide maternity benefits, the maternity (length of 
stay) and newborn care benefits must be provided in 
accordance with “Guidelines for Prenatal Care.” 
All Contracts 
0 
1996 
Benefits must be provided for medically necessary equipment 
and supplies used to treat diabetes and approved self-
management and education training. 
All Contracts 
0.20% 
1996 Benefits must be provided for screening Pap tests. All 0.01% 
1996 Benefits must be provided for annual gynecological exam without prior approval of primary care physician. Group managed care -- 
1997 
Benefits provided for breast cancer treatment for a medically 
appropriate period of time determined by the physician in 
consultation with the patient. 
All Contracts 
0.07% 
1998 Coverage required for off-label use of prescription drugs for treatment of cancer, HIV, or AIDS. All Contracts 0.30% 
1998 Coverage required for prostate cancer screening. All Contracts 0.07% 
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1999 Coverage of nurse practitioners and nurse midwives and allows nurse practitioners to serves as primary care providers. 
All Managed Care 
Contracts 
-- 
1999 Prescription drug must include contraceptives. All Contracts 0.80% 
1999 Coverage for registered nurse first assistants. All Contracts 0 
2000 Access to clinical trials. All Contracts 0.19% 
2000 Access to prescription drugs. All Managed Care Contracts 0 
2001 Coverage of hospice care services for terminally ill. All Contracts 0 
2001 Access to eye care. 
Plans with 
participating eye care 
professionals 0 
2001 Coverage of anesthesia and facility charges for certain dental procedures. All Contracts 0.05% 
2003 Coverage for prosthetic devices to replace an arm or leg Groups >20 0.03% 
All other 0.08% 
2003 Coverage of licensed clinical professional counselors All Contracts 0 
2005 Coverage of licensed pastoral counselors and marriage & family therapists All Contracts 0 
2007 Coverage of hearing aids for children All Contracts 0.1% 
2008 Coverage for amino acid-based elemental infant formulas All Contracts 0.1% 
2008 Coverage for colorectal cancer screening All Contracts 0 
2009 Coverage for independent dental hygienist All Contracts 0 
2010 Coverage for autism spectrum  All Contracts 0.3% 
2010 Coverage for children’s early intervention services  All Contracts 0.05% 
 Total cost for groups larger than 20:  8.11% 
 Total cost for groups of 20 or fewer:  8.16% 
 Total cost for individual contracts:  7.66% 
